Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...

Scotiabank initiated coverage of Zai Lab (ZLAB) with an Outperform rating and $55 price target The firm says that although geopolitical risk has capped the stock’s upside for years, Zai Lab is ...

JPMorgan raised the firm’s price target on Zai Lab (ZLAB) to $51 from $44 and keeps an Overweight rating on the shares. The firm updated models ...

Goldman Sachs analysts added Zai Lab (ZLAB) to the firm’s APAC Conviction List as part of its monthly update. The firm says the company is transitioning from a licensing-in based China-only ...

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, ...

Shares of ZLAB stock opened at $38.20 on Thursday. Zai Lab has a 1 year low of $13.48 and a 1 year high of $39.61. The stock’s 50 day simple moving average is $29.47 and its two-hundred day ...